Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 VIVUS Appoints New President | Contract Pharma

What are you searching for?

Sign in
Breaking News, Promotions & Moves

VIVUS Appoints New President

Ken Suh was previously president and CEO of a wholly-owned subsidiary of VIVUS, Willow Biopharma

By: Betsy Louda

, Contract Pharma

VIVUS announced the appointment of Ken Suh to the position of president.  Previously, Mr. Suh was president and chief executive officer of Willow Biopharma Inc., a wholly-owned subsidiary of VIVUS, Inc. As president of VIVUS, Mr. Suh will work to advance the Company toward its core objectives of product portfolio optimization and enterprise value creation. 
 
Mr. Suh founded Willow Biopharma in 2015, and in April 2018, Willow Biopharma became a wholly-owned subsidiary of VIVUS. Prior to establishing Willow, he founded KRIM Biopharma Inc., where he served as president, chief executive officer and director. 

“Ken has been instrumental in developing and executing our corporate strategy since joining VIVUS in April, and his appointment as President reflects the important contributions he has already made toward advancing our key business objectives, most notably, the recent acquisition of PANCREAZE,” said John Amos, chief executive officer at VIVUS. “Ken has a critical role to play in helping us build a sustainable and profitable specialty pharmaceutical company that creates value for patients and investors.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters